Eli Lilly and Co. won’t put the price of its prescription drugs in television ads, as the Trump administration has called for pharmaceutical companies to do, but will begin promoting a website where prices are available.
A New Jersey-based company that acquired Cook Group’s drug-delivery technology unit in late 2017 has plans for a major expansion.
New employees at Eli Lilly and Co. get a letter encouraging them to join one of the pharmaceutical firm’s affinity groups. There’s one for African Americans, one for Latino employees—and four for Asians.
The crisis has been years in the making, and the job of wrestling it to the ground has grown into a massive task. No one is yet predicting when the state will be able to declare victory.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
President Donald Trump said he was “taking aim at the global freeloading that forces American consumers to subsidize lower prices in foreign countries through higher prices in our country.”
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
The drug industry's main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they'll start doing that next spring.
An Indianapolis-based company has signed a deal with national mail-order pharmacy GoGoMeds that officials project will help double its local workforce—to about 250—within five years.
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
Overdose deaths in Indiana rose 18 percent last year compared with 2016 and 37 percent over 2015. A vast majority of the overdoses were caused by opioids.
A boom in major U.S. pharmaceutical stocks is creating a swarm of activity around an exchange-traded fund tracking major drugmakers like Eli Lilly and Co.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.